Novacyt S.A.
("Novacyt", the "Company" or the
"Group")
DHSC Claim
update - Pre-Trial Review
Paris, France, and Eastleigh and Manchester,
UK - 19 April 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM:
NCYT), an international molecular diagnostics company with a broad
portfolio of integrated technologies and services, provides an
update regarding its legal proceedings against the Department of
Health and Social Care ("DHSC").
As previously
announced, the Company and its subsidiary Primer Design Ltd are
party to litigation with the DHSC. The trial hearing has been
listed to commence on 10 June 2024, and finish on 4 July 2024. The
Company expects the court to reserve judgment, meaning that the
outcome of the trial will not be known on 4 July 2024.
The court has
listed the Pre-Trial Review to be heard on 30 April 2024. This is
part of the normal litigation process and is predominantly
concerned with administrative preparations for trial.
The court will
also hear an application by the DHSC for summary judgment in
relation to one aspect of its claim, as part of which the DHSC is
seeking judgment to be entered for the full value of its claim.
Having taken legal advice, the Company considers this application
to be very weak with low prospects of success, and is confident
that the court will dismiss the application. It is not known when
the court will give judgment in relation to the application.
It may be during or at the end of the Pre-Trial Review, or a short
time thereafter.
The Company will
announce the outcome of the application in due course.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
James
McCarthy, Acting Chief Executive Officer
|
Via Walbrook PR
|
|
Steve
Gibson, Chief Financial Officer
|
|
|
SP Angel Corporate Finance LLP
(Nominated Adviser and Broker)
|
+44 (0)20 3470 0470
|
|
Matthew
Johnson / Charlie Bouverat (Corporate Finance)
Vadim
Alexandre / Rob Rees (Corporate Broking)
|
|
|
|
|
|
Deutsche Numis
(Joint Broker)
|
+44 (0)20 7260 1000
|
|
Freddie
Barnfield / Duncan Monteith / Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing
Sponsor)
Rémi
Durgetto / Yannick Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR (Financial PR &
IR)
Stephanie Cuthbert / Paul McManus
/
Phillip
Marriage / Alice Woodings
|
+44 (0)20 7933 8780 or novacyt@walbrookpr.com
+44 (0)7796 794 663 / +44 (0)7980 541
893
+44 (0)7867 984 082 / +44 (0)7407 804
654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of
molecular assays and instrumentation to deliver workflows and
services that enable seamless end-to-end solutions from sample to
result across multiple sectors including human health, animal
health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical in vitro diagnostic products,
workflows and services focused on three therapeutic areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size selection DNA
sample preparation platforms and rapid PCR
machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
MyGo: real-time quantitative PCR
(qPCR) instruments
|
|
Research Use Only
|
Range of services for the research industry:
· Design,
manufacture, and supply of high-performance qPCR assays and
workflows for use in human health, agriculture, veterinary and
environmental, to support global health organisations and the
research industry
·
Pharmaceutical research services: whole genome sequencing (WGS) /
whole exome sequencing (WES)
|
Novacyt is headquartered in Vélizy
in France with offices in the UK (in Stokesley, Eastleigh and
Manchester), Taipei, Singapore, the US and Canada and has a
commercial presence in over 65 countries. The Company is listed on
the London Stock Exchange's AIM market ("NCYT") and on the Paris
Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com
